Cardiff Common Stock Shares Outstanding vs Net Tangible Assets Analysis

CRDF Stock

USD 2.61 0.07 2.76%

Cardiff Oncology financial indicator trend analysis is way more than just evaluating Cardiff Oncology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardiff Oncology is a good investment. Please check the relationship between Cardiff Oncology Common Stock Shares Outstanding and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.

Common Stock Shares Outstanding vs Net Tangible Assets

Common Stock Shares Outstanding vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardiff Oncology Common Stock Shares Outstanding account and Net Tangible Assets. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Cardiff Oncology's Common Stock Shares Outstanding and Net Tangible Assets is 0.9. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Cardiff Oncology, assuming nothing else is changed. The correlation between historical values of Cardiff Oncology's Common Stock Shares Outstanding and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Cardiff Oncology are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Common Stock Shares Outstanding i.e., Cardiff Oncology's Common Stock Shares Outstanding and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.9

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Cardiff Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardiff Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.The current Selling General Administrative is estimated to decrease to about 7.5 M. The current Issuance Of Capital Stock is estimated to decrease to about 16.3 M

	2021	2022	2023	2024 (projected)
Interest Income	264K	1.6M	3.8M	4.0M
Cost Of Revenue	500K	200K	32.9M	34.5M

Interest Income Cost Of Revenue

Cardiff Oncology fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Short Term Debt	Common Stock Total Equity	Inventory	Net Tangible Assets
Total Assets		0.99	-0.54	0.54	1.0	0.65	0.77	1.0	-0.28	0.05	0.54	0.67	0.57	-0.63	0.48	0.56	-0.1	0.78	-0.12	0.83	0.16	0.39	0.14	-0.26	0.45	0.85
Total Stockholder Equity	0.99		-0.53	0.5	0.99	0.69	0.77	0.99	-0.2	-0.08	0.51	0.6	0.5	-0.64	0.42	0.48	-0.17	0.8	-0.26	0.85	0.02	0.35	0.06	-0.18	0.45	0.87
Net Debt	-0.54	-0.53		-0.98	-0.56	-0.07	-0.31	-0.55	0.2	-0.06	-0.19	-0.28	0.0	0.19	-0.09	0.0	0.57	-0.11	0.02	-0.09	-0.1	0.02	-0.15	0.25	-0.23	-0.42
Cash	0.54	0.5	-0.98		0.56	0.03	0.28	0.55	-0.23	0.25	0.2	0.36	0.08	-0.16	0.16	0.09	-0.5	0.07	0.15	0.07	0.27	0.01	0.29	-0.32	0.22	0.38
Cash And Short Term Investments	1.0	0.99	-0.56	0.56		0.64	0.76	1.0	-0.28	0.05	0.52	0.65	0.54	-0.61	0.48	0.52	-0.13	0.76	-0.12	0.82	0.16	0.37	0.14	-0.27	0.43	0.85
Common Stock Shares Outstanding	0.65	0.69	-0.07	0.03	0.64		0.85	0.65	0.0	-0.3	0.8	0.57	0.43	-0.83	0.48	0.46	0.29	0.74	-0.49	0.76	-0.11	0.72	-0.07	0.05	0.44	0.9
Other Stockholder Equity	0.77	0.77	-0.31	0.28	0.76	0.85		0.76	-0.4	-0.17	0.89	0.68	0.63	-0.97	0.43	0.63	0.11	0.75	-0.41	0.81	0.0	0.77	-0.03	0.11	0.68	0.87
Total Current Assets	1.0	0.99	-0.55	0.55	1.0	0.65	0.76		-0.28	0.04	0.53	0.65	0.55	-0.62	0.48	0.53	-0.12	0.77	-0.13	0.83	0.15	0.37	0.13	-0.26	0.44	0.86
Common Stock	-0.28	-0.2	0.2	-0.23	-0.28	0.0	-0.4	-0.28		-0.11	-0.34	-0.18	-0.37	0.36	-0.16	-0.38	-0.09	-0.25	-0.18	-0.23	-0.25	-0.29	0.15	0.12	-0.22	-0.17
Short Long Term Debt Total	0.05	-0.08	-0.06	0.25	0.05	-0.3	-0.17	0.04	-0.11		0.0	0.42	0.39	0.2	0.38	0.4	0.29	-0.25	0.9	-0.13	0.94	0.11	0.77	-0.4	-0.03	-0.2
Other Current Liab	0.54	0.51	-0.19	0.2	0.52	0.8	0.89	0.53	-0.34	0.0		0.73	0.62	-0.91	0.44	0.66	0.33	0.49	-0.22	0.55	0.2	0.92	0.05	0.07	0.58	0.75
Total Current Liabilities	0.67	0.6	-0.28	0.36	0.65	0.57	0.68	0.65	-0.18	0.42	0.73		0.82	-0.68	0.57	0.84	0.26	0.45	0.12	0.58	0.52	0.73	0.55	-0.08	0.61	0.6
Property Plant And Equipment Net	0.57	0.5	0.0	0.08	0.54	0.43	0.63	0.55	-0.37	0.39	0.62	0.82		-0.64	0.34	0.98	0.42	0.52	0.16	0.68	0.48	0.7	0.41	-0.06	0.67	0.42
Retained Earnings	-0.63	-0.64	0.19	-0.16	-0.61	-0.83	-0.97	-0.62	0.36	0.2	-0.91	-0.68	-0.64		-0.4	-0.64	-0.17	-0.68	0.46	-0.74	0.04	-0.81	0.05	-0.25	-0.72	-0.77
Accounts Payable	0.48	0.42	-0.09	0.16	0.48	0.48	0.43	0.48	-0.16	0.38	0.44	0.57	0.34	-0.4		0.45	0.34	0.41	0.25	0.46	0.46	0.37	0.2	-0.29	0.01	0.45
Non Current Assets Total	0.56	0.48	0.0	0.09	0.52	0.46	0.63	0.53	-0.38	0.4	0.66	0.84	0.98	-0.64	0.45		0.52	0.54	0.21	0.66	0.53	0.72	0.37	-0.16	0.59	0.43
Non Currrent Assets Other	-0.1	-0.17	0.57	-0.5	-0.13	0.29	0.11	-0.12	-0.09	0.29	0.33	0.26	0.42	-0.17	0.34	0.52		0.11	0.32	0.14	0.44	0.57	0.19	-0.29	-0.05	0.06
Net Receivables	0.78	0.8	-0.11	0.07	0.76	0.74	0.75	0.77	-0.25	-0.25	0.49	0.45	0.52	-0.68	0.41	0.54	0.11		-0.37	0.95	-0.13	0.36	-0.16	0.01	0.45	0.71
Non Current Liabilities Total	-0.12	-0.26	0.02	0.15	-0.12	-0.49	-0.41	-0.13	-0.18	0.9	-0.22	0.12	0.16	0.46	0.25	0.21	0.32	-0.37		-0.33	0.89	-0.1	0.55	-0.6	-0.31	-0.37
Other Current Assets	0.83	0.85	-0.09	0.07	0.82	0.76	0.81	0.83	-0.23	-0.13	0.55	0.58	0.68	-0.74	0.46	0.66	0.14	0.95	-0.33		-0.04	0.46	-0.02	0.03	0.54	0.74
Total Liab	0.16	0.02	-0.1	0.27	0.16	-0.11	0.0	0.15	-0.25	0.94	0.2	0.52	0.48	0.04	0.46	0.53	0.44	-0.13	0.89	-0.04		0.32	0.7	-0.55	0.01	-0.01
Property Plant And Equipment Gross	0.39	0.35	0.02	0.01	0.37	0.72	0.77	0.37	-0.29	0.11	0.92	0.73	0.7	-0.81	0.37	0.72	0.57	0.36	-0.1	0.46	0.32		0.23	0.01	0.57	0.63
Short Term Debt	0.14	0.06	-0.15	0.29	0.14	-0.07	-0.03	0.13	0.15	0.77	0.05	0.55	0.41	0.05	0.2	0.37	0.19	-0.16	0.55	-0.02	0.7	0.23		-0.19	0.26	0.0
Common Stock Total Equity	-0.26	-0.18	0.25	-0.32	-0.27	0.05	0.11	-0.26	0.12	-0.4	0.07	-0.08	-0.06	-0.25	-0.29	-0.16	-0.29	0.01	-0.6	0.03	-0.55	0.01	-0.19		0.45	-0.13
Inventory	0.45	0.45	-0.23	0.22	0.43	0.44	0.68	0.44	-0.22	-0.03	0.58	0.61	0.67	-0.72	0.01	0.59	-0.05	0.45	-0.31	0.54	0.01	0.57	0.26	0.45		0.47
Net Tangible Assets	0.85	0.87	-0.42	0.38	0.85	0.9	0.87	0.86	-0.17	-0.2	0.75	0.6	0.42	-0.77	0.45	0.43	0.06	0.71	-0.37	0.74	-0.01	0.63	0.0	-0.13	0.47

Click cells to compare fundamentals

Cardiff Oncology Account Relationship Matchups

Cardiff Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	13.1M	134.7M	149.5M	116.2M	81.6M	45.3M
Total Stockholder Equity	7.3M	128.2M	140.4M	106.3M	69.7M	36.9M
Net Debt	(8.5M)	(130.1M)	(8.8M)	(13.6M)	(19.5M)	(20.5M)
Cash	10.2M	131.0M	11.9M	16.3M	21.7M	24.3M
Cash And Short Term Investments	10.2M	131.0M	140.8M	105.3M	74.8M	41.8M
Common Stock Shares Outstanding	6.0M	20.9M	39.0M	43.6M	44.7M	46.9M
Liabilities And Stockholders Equity	13.1M	134.7M	149.5M	116.2M	81.6M	45.3M
Other Stockholder Equity	217.2M	359.6M	400.4M	404.8M	409.3M	429.8M
Total Current Assets	11.4M	133.4M	146.1M	111.3M	77.4M	43.3M
Common Stock	7.7K	8.3K	3.7K	4K	3.6K	3.4K
Other Current Liab	3.3M	3.9M	4.0M	4.5M	7.1M	7.4M
Total Current Liabilities	4.8M	6.1M	6.6M	7.8M	10.4M	5.4M
Property Plant And Equipment Net	1.6M	966.7K	3.2M	3.5M	2.9M	1.8M
Retained Earnings	(208.9M)	(231.5M)	(259.8M)	(298.1M)	(339.5M)	(322.6M)
Accounts Payable	656K	1.4M	1.4M	2.0M	2.0M	1.3M
Non Current Assets Total	1.7M	1.4M	3.4M	4.9M	4.2M	2.3M
Non Currrent Assets Other	103K	(813.7K)	(1.8M)	1.4M	1.3M	1.3M
Net Receivables	204K	320.5K	535K	771K	288K	225.2K
Non Current Liabilities Total	994K	450.5K	2.6M	2.0M	1.5M	1.4M
Other Current Assets	955K	2.1M	4.8M	5.2M	2.3M	1.5M
Total Liab	5.8M	6.6M	9.1M	9.8M	11.9M	11.2M
Property Plant And Equipment Gross	1.6M	966.7K	3.2M	3.5M	6.7M	7.0M
Accumulated Other Comprehensive Income	(971.7K)	(2.2M)	(142K)	(395K)	(67K)	(70.4K)
Common Stock Total Equity	7.7K	8.3K	3.7K	4K	4.6K	4.7K
Net Tangible Assets	7.3M	128.2M	140.4M	106.3M	122.3M	128.4M
Retained Earnings Total Equity	(208.9M)	(231.5M)	(259.8M)	(298.1M)	(268.3M)	(281.7M)
Capital Surpluse	217.2M	361.8M	400.5M	404.8M	465.6M	249.6M
Deferred Long Term Liab	1.8M	1.1M	4.1K	285.0K	256.5K	243.7K
Property Plant Equipment	877.8K	623.7K	382K	1.3M	1.1M	1.2M
Other Assets	157.6K	404.2K	239K	1.4M	1.0	0.95
Other Liab	1.8M	1.2M	132.5K	441.2K	397.1K	377.3K
Net Invested Capital	7.3M	128.2M	140.4M	106.3M	69.7M	73.8M
Net Working Capital	6.6M	127.2M	139.6M	103.5M	67.0M	72.2M

Currently Active Assets on Macroaxis

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft
HBI	Hanesbrands
STLD	Steel Dynamics

When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:

How To Invest In Cardiff

Details

Is Cardiff Stock a good investment?

Details

What is Cardiff Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.95)

Revenue Per Share

0.015

Quarterly Revenue Growth

0.17

Return On Assets

(0.38)

Return On Equity

(0.68)

The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cardiff Common Stock Shares Outstanding vs Net Tangible Assets Analysis

Common Stock Shares Outstanding vs Net Tangible Assets

Common Stock Shares Outstanding vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Net Tangible Assets

Cardiff Oncology fundamental ratios Correlations

Cardiff Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cardiff Oncology fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Total Stockholder Equity

Cash	- 0.98	Net Debt
Retained Earnings	- 0.97	Other Stockholder Equity
Retained Earnings	- 0.91	Other Current Liab
Retained Earnings	- 0.83	Common Stock Shares Outstanding
Property Plant And Equipment Gross	- 0.81	Retained Earnings
Net Tangible Assets	- 0.77	Retained Earnings